|
|
|
|
TopAbstracts in Cirrhosis 11/18/2008
TopAbstracts in Cirrhosis are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 28 days.Over 2000 peer-reviewed...
|
|
|
AASLD: Mortality Risk in HCV-Positive Transplant Patients Similar Regardless of Donor Status
SAN FRANCISCO, Nov.4 -- Hepatitis C-positive liver transplant recipients live just as long whether the donor is HCV-positive or -negative, data from the national transplant network suggest. HCV-positive organ recipients lived an average...
|
|
|
Pegylated-Interferon and Ribavirin in Liver Transplant Candidates and Recipients With HCV Cirrhosis: Systemati
_ Pegylated-Interferon and Ribavirin in Liver Transplant Candidates and Recipients With HCV Cirrhosis: Systemati.
|
|
|
Reversal of Fibrosis and Cirrhosis Seen With Long-Term Entecavir for Chronic HBV
_ Reversal of Fibrosis and Cirrhosis Seen With Long-Term Entecavir for Chronic HBV.
|
|
|
Reversal of Fibrosis and Cirrhosis Seen With Long-Term Entecavir for Chronic HBV
_ Reversal of Fibrosis and Cirrhosis Seen With Long-Term Entecavir for Chronic HBV.
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD SAN DIEGO, November 01, 2008 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc.announced today the results...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today the results of a Phase...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healt
Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today the results of a Phase...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today the results of a Phase...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today the results of a Phase...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
Sexual Problems In Women Don't Always Result in Distress(4 hrs ago) The Key That Unlocks Hundreds of New Antibiotics found(5 hrs ago) News - Quick Links Special Reports Popular News Topics Health News and Press Release Font Size Anadys...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today the results of a Phase...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
Phase I Clinical Data and Additional Preclinical Results for Non-Nucleoside HCV Polymerase Inhibitor Being Presented at AASLD SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
/PRNewswire-FirstCall via COMTEX/ -- ANDS | Quote | Chart | News | PowerRating -- Anadys Pharmaceuticals, Inc.(Nasdaq: ANDS | Quote | Chart | News | PowerRating) announced today the results of a Phase I clinical trial of ANA598 in healthy...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of the leading...
|
|
|
Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunte
SAN DIEGO, Nov.1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today the results of a Phase I clinical trial of ANA598 in healthy volunteers and additional preclinical data that support ANA598 as one of...
|
